- Home
- VCIG vs LPCN Comparison
VCIG vs LPCN Comparison
Compare VCIG & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCIG
- LPCN
- Stock Information
- Founded
- VCIG 2013
- LPCN 1997
- Country
- VCIG Malaysia
- LPCN United States
- Employees
- VCIG N/A
- LPCN N/A
- Industry
- VCIG Diversified Commercial Services
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- VCIG Consumer Discretionary
- LPCN Health Care
- Exchange
- VCIG Nasdaq
- LPCN Nasdaq
- Market Cap
- VCIG 10.2M
- LPCN 16.1M
- IPO Year
- VCIG 2023
- LPCN N/A
- Fundamental
- Price
- VCIG $1.84
- LPCN $3.11
- Analyst Decision
- VCIG
- LPCN Strong Buy
- Analyst Count
- VCIG 0
- LPCN 2
- Target Price
- VCIG N/A
- LPCN $9.00
- AVG Volume (30 Days)
- VCIG 2.1M
- LPCN 60.9K
- Earning Date
- VCIG 08-18-2025
- LPCN 08-07-2025
- Dividend Yield
- VCIG N/A
- LPCN N/A
- EPS Growth
- VCIG N/A
- LPCN N/A
- EPS
- VCIG 54.73
- LPCN N/A
- Revenue
- VCIG $27,819,290.00
- LPCN $3,674,834.00
- Revenue This Year
- VCIG N/A
- LPCN N/A
- Revenue Next Year
- VCIG N/A
- LPCN N/A
- P/E Ratio
- VCIG $0.04
- LPCN N/A
- Revenue Growth
- VCIG 36.99
- LPCN N/A
- 52 Week Low
- VCIG $1.67
- LPCN $2.68
- 52 Week High
- VCIG $607.50
- LPCN $8.71
- Technical
- Relative Strength Index (RSI)
- VCIG 33.32
- LPCN 44.07
- Support Level
- VCIG $2.05
- LPCN $3.13
- Resistance Level
- VCIG $2.45
- LPCN $3.53
- Average True Range (ATR)
- VCIG 0.29
- LPCN 0.18
- MACD
- VCIG 0.00
- LPCN -0.00
- Stochastic Oscillator
- VCIG 10.96
- LPCN 20.75
About VCIG VCI Global Limited
VCI Global Ltd is a holding company. The principal activities of the Company and its subsidiaries are the provision of business Strategy consultancy and technology development. The firm organized its consulting services into three main segments: Business Strategy Consultancy; Technology development, solutions and consultancy; and Others. It derives the majority of its revenue from the Business Strategy Consultancy segment, which focuses on listing solutions, investor relations, and boardroom strategies consultancy.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.